DE2908241C2 - Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung - Google Patents

Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung

Info

Publication number
DE2908241C2
DE2908241C2 DE2908241A DE2908241A DE2908241C2 DE 2908241 C2 DE2908241 C2 DE 2908241C2 DE 2908241 A DE2908241 A DE 2908241A DE 2908241 A DE2908241 A DE 2908241A DE 2908241 C2 DE2908241 C2 DE 2908241C2
Authority
DE
Germany
Prior art keywords
tumor
substances
cells
substance
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2908241A
Other languages
German (de)
English (en)
Other versions
DE2908241A1 (de
Inventor
Yoshikazu Kanagawa Fujisawa
Yoshio Yokohama Kanagawa Furutani
Hitoshi Chiba Inoue
Shizuo Shimada
Tadashi Sudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Publication of DE2908241A1 publication Critical patent/DE2908241A1/de
Application granted granted Critical
Publication of DE2908241C2 publication Critical patent/DE2908241C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE2908241A 1978-03-10 1979-03-02 Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung Expired DE2908241C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2651978A JPS54140710A (en) 1978-03-10 1978-03-10 Anti-tumor substance and its preparation

Publications (2)

Publication Number Publication Date
DE2908241A1 DE2908241A1 (de) 1979-09-13
DE2908241C2 true DE2908241C2 (de) 1985-10-31

Family

ID=12195716

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2908241A Expired DE2908241C2 (de) 1978-03-10 1979-03-02 Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung
DE2954387A Expired DE2954387C2 (de) 1978-03-10 1979-03-02 Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2954387A Expired DE2954387C2 (de) 1978-03-10 1979-03-02 Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung

Country Status (7)

Country Link
US (1) US4726947A (enExample)
JP (1) JPS54140710A (enExample)
CA (1) CA1146467A (enExample)
DE (2) DE2908241C2 (enExample)
FR (1) FR2419071A1 (enExample)
GB (1) GB2015876B (enExample)
IT (1) IT1110450B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPS5632490A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
FR2466247A1 (fr) * 1979-10-03 1981-04-10 Decroix Guy Preparation immuno-stimulante et application
DE3048699C2 (de) * 1980-12-23 1985-03-28 Chisato Tokio/Tokyo Maruyama Immuntherapeutisches Mittel gegen Tumore, enthaltend als wirksame Komponente ein Lipopolysaccharid
KR940005589B1 (ko) * 1986-04-02 1994-06-21 다이닛뽄세이야꾸 가부시끼가이샤 핵산 또는 엔도톡신의 제거제 및 제거방법
US5527770A (en) * 1993-08-06 1996-06-18 International Gene Group, Inc. Immunotherapeutic agent derived from bacteria
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
DE4422859C2 (de) * 1994-06-30 2000-10-05 Laves Arzneimittel Gmbh Wäßrige Zellextrakte aus Mykobacterien
US5759992A (en) * 1994-08-31 1998-06-02 David Platt Immunotherapeutic agent derived from bacteria and method for its manufacture
EP0710484A3 (en) * 1994-10-07 1996-10-23 Univ Illinois Mixture of alpha-D-glucopyranosyl- (1-6) -alpha-D glucopyranose as an anti-tumor agent
EP0796280B1 (en) 1994-12-28 2003-03-26 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
WO1996021672A1 (en) * 1995-01-09 1996-07-18 International Gene Group, Inc. Immunotherapeutic agent derived from bacteria
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) * 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
AU727781B2 (en) * 1997-04-02 2000-12-21 Bioniche Life Sciences Inc. Use of bacterial cell wall extract for preventing, treating, or eliminating a protozoal or parasitic disease
CN1292073C (zh) * 1997-06-03 2006-12-27 森庸厚 天然抗肿瘤性或抗病毒性物质及其用途
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US20020068068A1 (en) * 1999-02-02 2002-06-06 Mahan Michael J. Method of creating antibodies and compositions used for same
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1867718B1 (en) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
CA2395493C (en) * 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
JP4859341B2 (ja) * 2001-07-19 2012-01-25 昭 林 ヒト免疫療法
US7153265B2 (en) * 2002-04-22 2006-12-26 Medtronic Minimed, Inc. Anti-inflammatory biosensor for reduced biofouling and enhanced sensor performance
US20040265337A1 (en) * 2002-08-21 2004-12-30 Zsebo Krisztina M. Method of generating an immune response and compositions used for same
WO2005082389A1 (ja) * 2004-02-27 2005-09-09 Fuji Oil Company, Limited 癌転移抑制組成物
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
WO2014001571A1 (en) * 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis
EP3106539A1 (en) * 2014-02-12 2016-12-21 Hyeong Gon Lee Thin film cluster production system, thin film cluster, thin film, uv protector, and cosmetics
CN114621946B (zh) * 2022-04-07 2023-07-04 施可丰化工股份有限公司 一种防治大豆根腐病的生防菌剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399263A (en) * 1965-04-12 1968-08-27 American Cyanamid Co Stable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acid
GB1188519A (en) * 1966-10-27 1970-04-15 Wellcome Found Method for the Purification of Lipopolysaccharides
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
GB1426042A (en) * 1971-11-26 1976-02-25 Anvar water-soluble immunological adjuvants
FR2189021A1 (en) * 1972-06-20 1974-01-25 Anvar Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues
US4001395A (en) * 1972-06-20 1977-01-04 Agence Nationale De Valorisation De La Recherche (Anvar) Hydrosoluble extracts of mycobacteria
NL7308450A (enExample) * 1972-06-20 1973-12-27
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
SU552744A1 (ru) * 1975-12-25 1977-11-05 Московский Научно-Исследовательский Институт Вакцин И Сывороток Им. И.И. Мечникова Министерства Здравоохранения Ссср Способ получени растворимого коклюшного иммуноадъюванта

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS-ERMITTELT

Also Published As

Publication number Publication date
GB2015876B (en) 1982-08-18
US4726947A (en) 1988-02-23
DE2954387C2 (de) 1986-10-09
IT1110450B (it) 1985-12-23
CA1146467A (en) 1983-05-17
JPS54140710A (en) 1979-11-01
GB2015876A (en) 1979-09-19
IT7920841A0 (it) 1979-03-08
JPS6241214B2 (enExample) 1987-09-02
DE2908241A1 (de) 1979-09-13
FR2419071A1 (fr) 1979-10-05
FR2419071B1 (enExample) 1983-02-11

Similar Documents

Publication Publication Date Title
DE2908241C2 (de) Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung
DE102007025045B4 (de) Schlankmachende kosmetische Zusammensetzung mit einem Biomasseextrakt aus der Alge Neochloris oleoabundans
DE3712768C2 (enExample)
DE2834308C2 (de) Verfahren zur Wasserabspaltung aus einer kolloidalen Liposomen-Dispersion
DE3921416C2 (de) Modifizierte Lipopolysaccharide, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE3407823C2 (enExample)
DE3887431T2 (de) Verfahren zur Herstellung und Extraktion von Polysacchariden aus einer Kultur von Porphyridium cruentum und Vorrichtung, um dieses Verfahren auszuführen.
DE2725204C2 (de) Verfahren zum Herstellen eines die unspezifische Immunität stimulierenden löslichen Mikroorganismenextrakts und diesem enthaltendes Arzneimittel
CH678492A5 (enExample)
DE2331144A1 (de) Wasserloesliche extrakte von mycobacterien
DE2638762A1 (de) Wasserloesliche adjuvantien, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2457090C2 (de) Verfahren zur Herstellung von Impfstoffen sowie Antibronchialimpfstoff
DE2547105A1 (de) N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien
DE2325299A1 (de) Aus mikroorganismen von der art der mycobakterien erhaltene, nicht-spezifische reizmittel, die eine antitumorimmunitaet hervorrufen und verfahren zu deren herstellung
CH641354A5 (de) Material mit antitumorwirkung und verfahren zu dessen herstellung.
CH526959A (de) Verfahren zur Herstellung eines avirulenten Antitumorpräparates aus Streptococcus hemolyticus
DE2823750C3 (de) Verfahren zur Gewinnung mindestens eines Hydrolyseprodukts eines Endotoxins von Bordetella Pertussis
CH643459A5 (de) Mikrobielles zellwandgeruest mit adjuvans- und antitumorwirkung enthaltende, verfestigte pharmazeutische zubereitung und ihre herstellung.
DE2262427C3 (de) Immunostimulierendes Mittel
EP0445710A1 (de) Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen
DE60213785T2 (de) Saponin inaktivierte mykoplasma impfstoffe
DE2828947A1 (de) Diagnose und behandlung von neoplasma
DE3431058C2 (enExample)
DE2513848A1 (de) Verfahren zur gewinnung ununterbrochener staemme von tumorzellen in vitro
DE3323093C2 (de) Pharmazeutisches Präparat zur Bekämpfung von Tumoren

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8125 Change of the main classification

Ipc: C12N 1/20

8172 Supplementary division/partition in:

Ref country code: DE

Ref document number: 2954386

Format of ref document f/p: P

Q171 Divided out to:

Ref country code: DE

Ref document number: 2954386

8181 Inventor (new situation)

Free format text: SHIMADA, SHIZUO SUDO, TADASHI INOUE, HITOSHI, CHIBA, JP FURUTANI, YOSHIO, YOKOHAMA, KANAGAWA, JP FUJISAWA, YOSHIKAZU, KANAGAWA, JP

8172 Supplementary division/partition in:

Ref country code: DE

Ref document number: 2954387

Format of ref document f/p: P

Q171 Divided out to:

Ref country code: DE

Ref document number: 2954387

D2 Grant after examination
8364 No opposition during term of opposition
AH Division in

Ref country code: DE

Ref document number: 2954387

Format of ref document f/p: P

8339 Ceased/non-payment of the annual fee